Magnetic Group Signaling (MGS®) Technology

Magnetic Group Signaling (MGS®) standardizes NMR systems and sample processing to ensure reproducible results on different NMR instruments.

Learn more

Numares. |One Sample - All Answers.


Locations: Boston, MA;
Regensburg, GE


employees of medical and
scientific disciplines


Founded as a spin-off of
Regensburg University

2.5 M+

analyses worldwide with Numares

Mastering Metabolite Constellations. |For Precision Diagnostics.

Numares is an innovative diagnostics company. We focus on the discovery, development and commercialization of diagnostic tests, using metabolite constellations to solve unmet medical needs not addressed by single biomarker-based medicine.

Our diagnostic tests are based on the interpretation of biomarkers in the metabolism, whose dynamics and relation to each other allow for predicting disease progression. These metabolite constellations create diagnostics of a new generation: non-invasive, timely and meaningful at manageable costs.

Company Milestones


Exclusive license agreement with Oxford University


FDA Submission of AXINON® GFR(NMR)


Numares announces FDA 510(k) Submission of AXINON System®, a NMR platform for metabolomics-based, AI-driven Diagnostics


Numares and Bruker Corporation sign agreement to enable advanced metabolomics-based clinical diagnostics


Numares announces collaboration with Mayo Clinic Laboratories on the development of new diagnostic tests


Numares completes another financing round


Start of pan-European multicenter study PARASOL to evaluate metabolite constellations to detect kidney allograft rejection


Launch of AXINON® renalTX-SCORE®-U100: first metabolomics IVD test for allograft rejection diagnostics after kidney transplantation


Collaboration with Oxford University on the development of Multiple Sclerosis diagnostic test


1,000.000 performed analyses


Numares completes another financing round


Launch of CE-marked IVD test AXINON® lipoFIT®-S100 for comprehensive NMR-based lipoprotein profiling


600.000 performed analyses


Successful completion of studies on kidney transplantation


Cooperation with a German laboratory network: commissioning of a test system for lipoprotein profiling


200.000 performed analyses


Bulk order from a U.S. laboratory chain: installation of multiple test systems for lipoprotein profiling


Successful certification of Numares according to EN ISO 13485: 2012 as a manufacturer of in-vitro diagnostics (IVD)


100.000 performed analyses


Certification as per EN ISO 13485:2003

As off 2005

Measurements within large studies such as GRAPHIC and KORA


First patent for the determination of lipoproteins in body fluids (lipoprotein profiling)


“With software-based diagnostic tests for our modular AXINON® IVD System, we are focusing on improving patient care at affordable healthcare costs.”

Dr. Claus Botzler, MBA

Executive Board, CTO

“AXINON® combines flexibility, personalization and high-tech - ideal conditions to make diagnostics available for everyone, to minimize healthcare costs and maximize shareholder value.”

Florian Voss

Executive Board, COO

“Although our AXINON® IVD System requires only minimal operator interaction, it is our claim to accompany our clients with the best support – beyond set-up and maintenance.”

Dr. Lutz Niggl

Head of Service

Supervisory Board

Uwe Steinbacher

- Chairman of the Supervisory Board
- Managing Partner, SHS Capital
- Previously with Brockhaus Private Equity

Dr. Volker Pfahlert

- Former CEO at Numares
- Previously with Roche and McKinsey

Dr. Rainer Kutzner

- Previously Managing Director of Mayfair SE
- Previously board member at Tchibo
- Supervisory board member at Puma

Kathy L. Bates, MBA

- Previously Senior Director at Mayo Clinic
- Steering committee member of Numares-Mayo collaboration
- Previously with Oncospire Genetics and Roche

Dr. Gerhard Ries

- Founder and CEO of DiaMedCare
- Previously with Novartis Ciba Geigy
- Previously with McKinsey
- Founder and CEO of kineo finance AG (formerly DiaMedCare AG)

Dr. Gregory F. Heath

- Scientific Advisory Board of Everly Health
- Strategic and scientific advisor
- Previously with Roche and Illumina

You did not activate the necessary cookies for this content.

activate necessary cookies and show content